Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This review in depth considers the thiopurines azathioprine, 6-mercaptopurine and 6-thioguanine, methotrexate, ciclosporin, infliximab and less well-established immunomodulators (including thalidomide, mycophenolate, tacrolimus and natalizumab among others) in their role of modifying the course of ulcerative colitis and Crohn's disease. The five papers are preceded by an overview on the therapeutic order of precedence, the indications and duration of therapy, as well as future concepts.

Original publication

DOI

10.1097/00042737-200303000-00001

Type

Journal article

Journal

European journal of gastroenterology & hepatology

Publication Date

03/2003

Volume

15

Pages

215 - 218

Addresses

John Radcliffe Hospital, Oxford, UK. simon.travis@orh.nhs.uk

Keywords

Humans, Colitis, Ulcerative, Inflammatory Bowel Diseases, Crohn Disease, Immunosuppressive Agents